Gene therapy for diseases of the cornea - a review

Clinical and Experimental Ophthalmology

Volumn 38, Issue 2, 2010, Pages 93-103

  Williams, Keryn A ^a   Coster, Douglas J ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Cornea; Gene transfer; Regulatory issue; Safety; Transgene delivery; Transgenic protein

Indexed keywords

ABATACEPT; ADENOVIRUS VECTOR; ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; ARYLSULFATASE; BETA GLUCURONIDASE; DENDRIMER; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 4; LENTIVIRUS VECTOR; LIPOSOME; MACROPHAGE INFLAMMATORY PROTEIN 2; NAKED DNA; NANOPARTICLE; NERVE GROWTH FACTOR; ORNITHINE CARBAMOYLTRANSFERASE; PLASMID DNA; PROTEIN BCL XL; RIBOZYME; SMAD7 PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VASCULOTROPIN RECEPTOR 1;

CLINICAL TRIAL; CORNEA DISEASE; CORNEA DYSTROPHY; CORNEA ENDOTHELIUM; CORNEA NEOVASCULARIZATION; CORNEA TRANSPLANTATION; DNA MODIFICATION; DRUG FATALITY; ELECTROPORATION; EX VIVO GENE TRANSFER; EYE DISEASE; EYEBANK; GENE GUN; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENE THERAPY; GENETIC DISORDER; GOOD MANUFACTURING PRACTICE; GRAFT REJECTION; HERPES SIMPLEX KERATITIS; HUMAN; IONTOPHORESIS; LIPOSOMAL GENE DELIVERY SYSTEM; MAROTEAUX LAMY SYNDROME; MUCOPOLYSACCHARIDOSIS TYPE 7; NONHUMAN; ORNITHINE TRANSCARBAMYLASE DEFICIENCY; REVIEW; RHEUMATOID ARTHRITIS; SCAR FORMATION; T CELL LEUKEMIA; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

ANIMALS; CORNEAL DISEASES; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS;

EID: 77952035571     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2009.02179.x     Document Type: Review

References (97)

1. Ashworth JL, Biswas S, Wraith E, Lloyd IC. The ocular features of the mucopolysaccharidoses. Eye 2006, 20:553-63.
2. Pieramici SF, Afshari NA. Genetics of corneal dystrophies: the evolving landscape. Curr Opin Ophthalmol 2006, 17:361-6.
3. Poulaki V, Colby K. Genetics of anterior and stromal corneal dystrophies. Semin Ophthalmol 2008, 23:9-17.
4. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol 2001, 12:242-9.
5. Saika S, Yamanaka O, Sumioka T. Fibrotic disorders in the eye: targets of gene therapy. Prog Retin Eye Res 2008, 27:177-96.
6. Williams KA, Jessup CF, Coster DJ. Gene therapy approaches to prolonging corneal allograft survival. Expert Opin Biol Ther 2004, 4:1059-71.
7. McAlister JC, Joyce NC, Harris DL, Ali RR, Larkin DF. Induction of replication in human corneal endothelial cells by E2F2 transcription factor cDNA transfer. Invest Ophthalmol Vis Sci 2005, 46:3597-603.
8. Garrido E, Cormand B, Hopwood JJ, Chabás A, Grinberg D, Vilageliu L. Maroteaux-Lamy syndrome: functional characterization of pathogenic mutations and polymorphisms in the arylsulfatase B gene. Mol Genet Metab 2008, 94:305-12.
9. Tomatsu S, Montaño AM, Dung VC, Grubb JH, Sly WS. Mutations and polymorphisms in GUSB gene in mucopolysaccharidosis VII (Sly Syndrome). Hum Mutat 2009, 30:511-9.
10. Aldave AJ, Sonmez B. Elucidating the molecular genetic basis of the corneal dystrophies: are we there yet? Arch Ophthalmol 2007, 125:177-86.
11. Williams KA, Lowe MT, Bartlett CM, Kelly L, Coster DJ. The Australian Corneal Graft Registry Report 2007 2008, 1-194. eds, Adelaide, Flinders University Press
12. Ambati BK, Nozaki M, Singh N. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006, 443:993-7.
13. Bachmann BO, Bock F, Wiegand SJ. Promotion of graft survival by vascular endothelial growth factor A neutralization after high-risk corneal transplantation. Arch Ophthalmol 2008, 126:71-7.
14. Murthy RC, McFarland TJ, Yoken J. Corneal transduction to inhibit angiogenesis and graft failure. Invest Ophthalmol Vis Sci 2003, 44:1837-42.
15. Saika S, Ikeda K, Yamanaka O. Expression of Smad7 in mouse eyes accelerates healing of corneal tissue following exposure to alkali. Am J Pathol 2005, 166:1405-18.
16. Coster DJ, Williams KA. The impact of corneal allograft rejection on the long-term outcome of corneal transplantation. Am J Ophthalmol 2005, 140:1112-22.
17. Parker DG, Brereton HM, Coster DJ, Williams KA. The potential of viral vector- mediated gene transfer to prolong corneal allograft survival. Curr Gene Ther 2009, 9:33-44.
18. Klebe S, Sykes PJ, Coster DJ, Krishnan R, Williams KA. Prolongation of sheep corneal allograft survival by ex vivo transfer of the gene encoding interleukin-10. Transplantation 2001, 71:1214-20.
19. Muller A, Zhang EP, Schroff M, Wittig B, Hoffmann F. Influence of ballistic gene transfer on antigen-presenting cells in murine corneas. Graefes Arch Clin Exp Ophthalmol 2002, 240:851-9.
20. Comer RM, King WJ, Ardjomand N, Theoharis S, George AJ, Larkin DF. Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival. Invest Ophthalmol Vis Sci 2002, 43:1095-103.
21. Zhang EP, Franke J, Schroff M, Junghans C, Wittig B, Hoffmann F. Ballistic CTLA4 and IL-4 gene transfer into the lower lid prolongs orthotopic corneal graft survival in mice. Graefes Arch Clin Exp Ophthalmol 2003, 241:921-6.
22. Klebe S, Coster DJ, Sykes PJ. Prolongation of sheep corneal allograft survival by transfer of the gene encoding ovine IL-12-p40 but not IL-4 to donor corneal endothelium. J Immunol 2005, 175:2219-26.
23. Gong N, Pleyer U, Yang J. Influence of local and systemic CTLA4Ig gene transfer on corneal allograft survival. J Gene Med 2006, 8:459-67.
24. Beutelspacher SC, Pillai R, Watson MP. Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur J Immunol 2006, 36:690-700.
25. Gong N, Pleyer U, Volk HD, Ritter T. Effects of local and systemic viral interleukin-10 gene transfer on corneal allograft survival. Gene Ther 2007, 14:484-90.
26. Pillai RG, Beutelspacher SC, Larkin DF, George AJ. Expression of the chemokine antagonist vMIP II using a non-viral vector can prolong corneal allograft survival. Transplantation 2008, 85:1640-7.
27. Gong N, Pleyer U, Vogt K. Local overexpression of nerve growth factor in rat corneal transplants improves allograft survival. Invest Ophthalmol Vis Sci 2007, 48:1043-52.
28. Barcia RN, Dana MR, Kazlauskas A. Corneal graft rejection is accompanied by apoptosis of the endothelium and is prevented by gene therapy with Bcl-xL. Am J Transplant 2007, 7:2082-9.
29. Schoser B, Hill V, Raben N. Therapeutic approaches in glycogen storage disease type II/Pompe disease. Neurotherapeutics 2008, 5:569-78.
30. Rovelli AM. The controversial and changing role of haematopoietic cell transplantation for lysosomal storage disorders: an update. Bone Marrow Transplant 2008, 41(2):S87-9. Suppl
31. Pitz S, Ogun O, Arash L, Miebach E, Beck M. Does enzyme replacement therapy influence the ocular changes in type VI mucopolysaccharidosis? Graefes Arch Clin Exp Ophthalmol 2009, 247:975-80.
32. Bergwerk KE, Falk RE, Glasgow BJ, Rabinowitz YS. Corneal transplantation in a patient with mucopolysaccharidosis type VII (Sly disease). Ophthalmic Genet 2000, 21:17-20.
33. Uçakhan OO, Brodie SE, Desnick R, Willner J, Asbell PA. Long-term follow-up of corneal graft survival following bone marrow transplantation in the Maroteaux-Lamy syndrome. CLAO J 2001, 27:234-7.
34. Varssano D, Cohen EJ, Nelson LB, Eagle RC. Corneal transplantation in Maroteaux-Lamy syndrome. Arch Ophthalmol 1997, 115:428-9.
35. Kamata Y, Tanabe A, Kanaji A. Long-term normalization in the central nervous system, ocular manifestations, and skeletal deformities by a single systemic adenovirus injection into neonatal mice with mucopolysaccharidosis VII. Gene Ther 2003, 10:406-14.
36. Wolfe JH, Sands MS, Barker JE. Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer. Nature 1992, 360:749-53.
37. Wolfe JH, Sands MS, Harel N. Gene transfer of low levels of beta-glucuronidase corrects hepatic lysosomal storage in a large animal model of mucopolysaccharidosis VII. Mol Ther 2000, 2:552-61.
38. Kamata Y, Okuyama T, Kosuga M. Adenovirus-mediated gene therapy for corneal clouding in mice with mucopolysaccharidosis type VII. Mol Ther 2001, 4:307-12.
39. Jun AS, Larkin DF. Prospects for gene therapy in corneal disease. Eye 2003, 17:906-11.
40. Mohan RR, Sharma A, Netto MV, Sinha S, Wilson SE. Gene therapy in the cornea. Prog Retin Eye Res 2005, 24:537-59.
41. George AJ, Arancibia-Cárcamo CV, Awad HM. Gene delivery to the corneal endothelium. Am J Respir Crit Care Med 2000, 162:S194-200.
42. Daheshia M, Kuklin N, Kanangat S, Manickan E, Rouse BT. Suppression of ongoing ocular inflammatory disease by topical administration of plasmid DNA encoding IL-10. J Immunol 1997, 159:1945-52.
43. Stechschulte SU, Joussen AM, von Recum HA. Rapid ocular angiogenic control via naked DNA delivery to cornea. Invest Ophthalmol Vis Sci 2001, 42:1975-9.
44. Yoon KC, Bae JA, Park HJ. Subconjunctival gene delivery of the transcription factor GA-binding protein delays corneal neovascularization in a mouse model. Gene Ther 2009, 16:973-81.
45. Tanelian DL, Barry MA, Johnston SA, Le T, Smith G. Controlled gene gun delivery and expression of DNA within the cornea. Biotechniques 1997, 23:484-8.
46. Klebe S, Stirling JW, Williams KA. Corneal endothelial cell nuclei are damaged after DNA transfer using a gene gun. Clin Experiment Ophthalmol 2000, 28:58-9.
47. Sundararajan R. Nanosecond electroporation: another look. Mol Biotechnol 2009, 41:69-82.
48. Del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today 2008, 13:135-43.
49. Hudde T, Rayner SA, Comer RM. Activated polyamidoamine dendrimers, a non- viral vector for gene transfer to the corneal endothelium. Gene Ther 1999, 6:939-43.
50. Mintzer MA, Simanek EE. Nonviral vectors for gene delivery. Chem Rev 2009, 109:259-302.
51. Tan PH, Manunta M, Ardjomand N. Antibody targeted gene transfer to endothelium. J Gene Med 2003, 5:311-23.
52. Parker AL, Collins L, Zhang X, Fabre JW. Exploration of peptide motifs for potent non-viral gene delivery highly selective for dividing cells. J Gene Med 2005, 7:1545-54.
53. de la Fuente M, Seijo B, Alonso MJ. Bioadhesive hyaluronan-chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue. Gene Ther 2008, 15:668-76.
54. Bemelmans AP, Arsenijevic Y, Majo F. Efficient lentiviral gene transfer into corneal stroma cells using a femtosecond laser: Gene Ther. 2009
55. Parker AL, Eckley L, Singh S, Preece JA, Collins L, Fabre JW. (LYS)(16)-based reducible polycations provide stable polyplexes with anionic fusogenic peptides and efficient gene delivery to post mitotic cells. Biochim Biophys Acta 2007, 1770:1331-7.
56. Zhang EP, Muller A, Schulte F. Minimizing side effects of ballistic gene transfer into the murine corneal epithelium. Graefes Arch Clin Exp Ophthalmol 2002, 240:114-9.
57. Zagon IS, Sassani JW, Malefyt KJ, McLaughlin PJ. Regulation of corneal repair by particle-mediated gene transfer of opioid growth factor receptor complementary DNA. Arch Ophthalmol 2006, 124:1620-4.
58. Oshima Y, Sakamoto T, Yamanaka I, Nishi T, Ishibashi T, Inomata H. Targeted gene transfer to corneal endothelium in vivo by electric pulse. Gene Ther 1998, 51:1347-54.
59. Oshima Y, Sakamoto T, Hisatomi T. Targeted gene transfer to corneal stroma in vivo by electric pulses. Exp Eye Res 2002, 74:191-8.
60. Berdugo M, Valamanesh F, Andrieu C. Delivery of antisense oligonucleotide to the cornea by iontophoresis. Antisense Nucl Acid Drug Dev 2003, 13:107-14.
61. Davies JB, Ciavatta VT, Boatright JH, Nickerson JM. Delivery of several forms of DNA, DNA-RNA hybrids, and dyes across human sclera by electrical fields. Mol Vis 2003, 9:569-78.
62. Pleyer U, Groth D, Hinz B. Efficiency and toxicity of liposome-mediated gene transfer to corneal endothelial cells. Exp Eye Res 2001, 73:1-7.
63. Klebe S, Sykes PJ, Coster DJ, Bloom DC, Williams KA. Gene transfer to ovine corneal endothelium. Clin Experiment Ophthalmol 2001, 29:316-22.
64. Yamashita T, Sonoda S, Suzuki R. A novel bubble liposome and ultrasound- mediated gene transfer to ocular surface: RC-1 cells in vitro and conjunctiva in vivo. Exp Eye Res 2007, 85:741-8.
65. Collins L, Fabre JW. A synthetic peptide vector system for optimal gene delivery to corneal endothelium. J Gene Med 2004, 6:185-94.
66. de la Fuente M, Seijo B, Alonso MJ. Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy. Invest Ophthalmol Vis Sci 2008, 49:2016-24.
67. Jani PD, Singh N, Jenkins C. Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. Invest Ophthalmol Vis Sci 2007, 48:2030-6.
68. Larkin DF, Oral HB, Ring CJ, Lemoine NR, George AJ. Adenovirus-mediated gene delivery to the corneal endothelium. Transplantation 1996, 61:363-70.
69. Ritter T, Gong N, Pleyer U. Is ex vivo adenovirus mediated gene transfer a therapeutic option for the treatment of corneal diseases? Br J Ophthalmol 2005, 89:648-9.
70. Bennett J. Immune response following intraocular delivery of recombinant viral vectors. Gene Ther 2003, 10:977-82.
71. Cockrell AS, Kafri T. Gene delivery by lentivirus vectors. Mol Biotechnol 2007, 36:184-204.
72. Loewen N, Poeschla EM. Lentiviral vectors. Adv Biochem Eng Biotechnol 2005, 99:169-91.
73. Bushman FD. Retroviral integration and human gene therapy. J Clin Invest 2007, 117:2083-6.
74. Sarkis C, Philippe S, Mallet J, Serguera C. Non-integrating lentiviral vectors. Curr Gene Ther 2008, 8:430-7.
75. Follenzi A, Santambrogio L, Annoni A. Immune responses to lentiviral vectors. Curr Gene Ther 2007, 7:306-15.
76. Allocca M, Tessitore A, Cotugno G, Auricchio A. AAV-mediated gene transfer for retinal diseases. Expert Opin Biol Ther 2006, 6:1279-94.
77. Blalock TD, Yuan R, Lewin AS, Schultz GS. Hammerhead ribozyme targeting connective tissue growth factor mRNA blocks transforming growth factor-beta mediated cell proliferation. Exp Eye Res 2004, 78:1127-36.
78. Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat Med 2003, 9:1026-32.
79. Law LY, Zhang WV, Stott NS, Becker DL, Green CR. In vitro optimization of antisense oligodeoxynucleotide design: an example using the connexin gene family. J Biomol Tech 2006, 17:270-82.
80. Chang CY, Laux-Fenton WT, Law LY, Becker DL, Sherwin T, Green CR. Antisense down regulation of connexin31.1 reduces apoptosis and increases thickness of human and animal corneal epithelia. Cell Biol Int 2009, 33:376-85.
81. Ripley AN, Chang MS, Bader DM. Bves is expressed in the epithelial components of the retina, lens, and cornea. Invest Ophthalmol Vis Sci 2004, 45:2475-83.
82. Seta F, Patil K, Bellner L. Inhibition of VEGF expression and corneal neovascularization by siRNA targeting cytochrome P450 4B1. Prostaglandins Other Lipid Mediat 2007, 84:116-27.
83. White RR, Shan S, Rusconi CP. Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc Natl Acad Sci USA 2003, 100:5028-33.
84. Teichler Zallen D. US gene therapy in crisis. Trends Genet 2000, 16:272-5.
85. Wilson JM. Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab 2009, 96:151-7.
86. Yarborough M, Sharp RR. Public trust and research a decade later: what have we learned since Jesse Gelsinger's death? Mol Genet Metab 2009, 97:4-5.
87. Williams DA. NIH recombinant DNA Advisory Committee continues to ponder adverse event associated with AAV gene therapy trial. Mol Ther 2008, 16:427-8.
88. Hacein-Bey-Abina S, Garrigue A, Wang GP. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008, 118:3132-42.
89. Montini E, Cesana D, Schmidt M. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 2009, 119:964-75.
90. Modlich U, Baum C. Preventing and exploiting the oncogenic potential of integrating gene vectors. J Clin Invest 2009, 119:755-8.
91. Manno CS, Pierce GF, Arruda VR. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006, 12:342-7.
92. Wright JF. Manufacturing and characterizing AAV-based vectors for use in clinical studies. Gene Ther 2008, 15:840-8.
93. http://www.wiley.co.uk/genetherapy/clinical/, The Journal of Gene Medicine Clinical Trial website, updated March 2009. Accessed 12 May 2009. Available from:
94. Bainbridge JW, Smith AJ, Barker SS. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008, 358:2231-9.
95. Maguire AM, Simonelli F, Pierce EA. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008, 358:2240-8.
96. Hauswirth WW, Aleman TS, Kaushal S. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008, 19:979-90.
97. Klausner EA, Peer D, Chapman RL, Multack RF, Andurkar SV. Corneal gene therapy. J Control Release 2007, 124:107-33.